113 related articles for article (PubMed ID: 10709798)
1. Identifying the maximum safe dose: a multiple testing approach.
Hothorn LA; Hauschke D
J Biopharm Stat; 2000 Feb; 10(1):15-30. PubMed ID: 10709798
[TBL] [Abstract][Full Text] [Related]
2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
3. A multiple comparison procedure to control the strong stagewise family error rate in comparing test treatments and a control.
Chen M; Kianifard F
J Biopharm Stat; 1997 Jul; 7(3):355-67. PubMed ID: 9252830
[TBL] [Abstract][Full Text] [Related]
4. Dose response studies. I. Some design considerations.
Ruberg SJ
J Biopharm Stat; 1995 Mar; 5(1):1-14. PubMed ID: 7613556
[TBL] [Abstract][Full Text] [Related]
5. Multiple comparisons and multiple contrasts in randomized dose-response trials--confidence interval oriented approaches.
Hothorn LA
J Biopharm Stat; 2006; 16(5):711-31. PubMed ID: 17037267
[TBL] [Abstract][Full Text] [Related]
6. Analyzing randomized dose finding studies with a primary and a secondary endpoint.
Hothorn LA; Wassmer G
J Biopharm Stat; 2003 May; 13(2):301-5. PubMed ID: 12729396
[TBL] [Abstract][Full Text] [Related]
7. Dose response studies. II. Analysis and interpretation.
Ruberg SJ
J Biopharm Stat; 1995 Mar; 5(1):15-42. PubMed ID: 7613559
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
[TBL] [Abstract][Full Text] [Related]
9. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
11. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
12. Precision of estimates of an ADI (or TDI or PTWI).
Speijers GJ
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
[TBL] [Abstract][Full Text] [Related]
13. How to deal with multiple treatment or dose groups in randomized clinical trials?
Hothorn LA
Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286
[TBL] [Abstract][Full Text] [Related]
14. Fallback tests in dose-response clinical trials.
Dmitrienko A; Wiens B; Westfall P
J Biopharm Stat; 2006; 16(5):745-55. PubMed ID: 17037269
[TBL] [Abstract][Full Text] [Related]
15. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
Slob W; Moerbeek M; Rauniomaa E; Piersma AH
Toxicol Sci; 2005 Mar; 84(1):167-85. PubMed ID: 15483190
[TBL] [Abstract][Full Text] [Related]
16. Paradigm lost, paradigm found: the re-emergence of hormesis as a fundamental dose response model in the toxicological sciences.
Calabrese EJ
Environ Pollut; 2005 Dec; 138(3):379-411. PubMed ID: 16098930
[TBL] [Abstract][Full Text] [Related]
17. An analysis of the risk of exceeding the acceptable or tolerable daily intake.
Renwick AG; Walker R
Regul Toxicol Pharmacol; 1993 Dec; 18(3):463-80. PubMed ID: 8128007
[TBL] [Abstract][Full Text] [Related]
18. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
[TBL] [Abstract][Full Text] [Related]
19. Substance-tailored testing strategies in toxicology: an in silico methodology based on QSAR modeling of toxicological thresholds and Monte Carlo simulations of toxicological testing.
Péry AR; Desmots S; Mombelli E
Regul Toxicol Pharmacol; 2010 Feb; 56(1):82-92. PubMed ID: 19766156
[TBL] [Abstract][Full Text] [Related]
20. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
Zhu Y; Wang T; Jelsovsky JZ
Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
